Vascular Biogenics Ltd. - Ordinary Shares (VBLT) News

Vascular Biogenics Ltd. - Ordinary Shares (VBLT): $0.23

-0.01 (-3.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter VBLT News Items

VBLT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VBLT News Highlights

  • For VBLT, its 30 day story count is now at 3.
  • Over the past 13 days, the trend for VBLT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • TEL and MA are the most mentioned tickers in articles about VBLT.

Latest VBLT News From Around the Web

Below are the latest news stories about Vascular Biogenics Ltd that investors may wish to consider to help them evaluate VBLT as an investment opportunity.

VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TEL AVIV, Israel and NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the Compensation Committee of VBL’s Board of Directors approved the grant effective February 13, 2022 of a non-qualified stock option to purchase an aggregate of 300,000 ordinary shares of VBL as an inducement ma

Yahoo | February 15, 2022

Vascular Biogenics (VBLT) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | February 14, 2022

VBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor Conference

TEL AVIV, Israel and NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will participate in a fireside chat at the Guggenheim Oncology Conference being held virtually on February 9 – 11, 2022. Management will also attend

Yahoo | February 2, 2022

VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer

CCO appointment positions VBL to advance and accelerate commercialization strategy for ofra-vec (VB-111) Enrollment in the OVAL Study, a 400 patient Phase 3 registration-enabling trial in ovarian cancer, expected to be completed this quarter; PFS co-primary endpoint readout expected in 2H22 has potential to support BLA filing TEL AVIV, Israel and NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class ther

Yahoo | January 18, 2022

VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

TEL AVIV, Israel and NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune-inflammatory indications, today announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will present a corporate overview at the H.C. Wainwright BioConnect Virtual Conference being held on January 10 – 13, 2022. H.C. Wainwright BioConnect Virtu

Yahoo | January 6, 2022

BridgeBio (BBIO) Tumbles on Cardiomyopathy Candidate Failure

BridgeBio's (BBIO) acoramidis fails to meet the primary endpoint of a six-minute walk test in cardiomyopathy patients. However, secondary data demonstrate a favorable trend. The study continues.

Yahoo | December 28, 2021

VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program

VBL is among only 9% of companies across industries selected by the EIC Accelerator Funds to be used for clinical development, CMC, and pre-commercialization activities for ofra-vec (VB-111) TEL AVIV, Israel and NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it has been selected for €

Yahoo | December 20, 2021

Reata (RETA) Falls on Negative Advisory Committee Outcome

An FDA advisory committee believes Reata's (RETA) bardoxolone study data does not support the effectiveness of the candidate in slowing the progression of CKD in patients with Alport syndrome.

Yahoo | December 9, 2021

Vascular Biogenics (NASDAQ:VBLT) Stock Price Crosses Below 50 Day Moving Average of $2.24

Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $2.24 and traded as low as $2.05. Vascular Biogenics shares last traded at $2.06, with a volume of 296,919 shares traded. Several research analysts recently commented on the company. HC []

Dakota Financial News | December 8, 2021

Reata (RETA) Plunges on FDA Concerns for Kidney Failure Drug

The FDA raises concerns related to data in Reata's (RETA) NDA seeking approval for bardoxolone for treating Alport syndrome. An advisory committee meeting is scheduled tomorrow.

Yahoo | December 7, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4947 seconds.